T1	Participants 273 352	patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
T2	Participants 431 465	Patients in stage IIIB or IV NSCLC
T3	Participants 784 866	105 (GA arm, 51; PG arm, 54) eligible patients (stage IV, 32 and 30, respectively)
